Chengdu Kanghua Biological Products (300841.SZ) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · China · ISIN CNE100003Y57
Price
51.40 CNY
Market cap
6.68 bn CNY
P/E (2025)
30.37
P/S (2025)
5.73
Dividend yield
0.97 %
Net margin
18.88 %
Return on equity (ROE)
6.22 %
Return on assets (ROA)
5.48 %
Chengdu Kanghua Biological Products financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 1.43 bn CNY | 1.17 bn CNY |
| Gross profit | 1.35 bn CNY | 1.07 bn CNY |
| Operating income | 467.28 m CNY | 273.12 m CNY |
| EBIT | 531.64 m CNY | 263.42 m CNY |
| Net income | 398.65 m CNY | 219.90 m CNY |
| Diluted EPS – continuing operations | 3.03 CNY | 1.69 CNY |
Full history since 2015, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Chengdu Kanghua Biological Products
Chengdu Kanghua Biological Products Co., Ltd. engages in the research, development, and operation of biological products in China. It offers freeze-dried human rabies vaccines; ACYW135 meningococcal polysaccharide vaccine. The company was founded in 2004 and is based in Chengdu, China.
More stocks
- NATIONAL PRESTO INDUSTRIES INC (NPK)
- JYP Entertainment Corporation (035900.KQ)
- Zhejiang Garden Bio-chemical High-tech Co Ltd (300401.SZ)
- Douglas (DOU.DE)
- Storytel AB (publ) (STORY B.ST)
- Sansteel MinGuang Co Ltd Fujian (002110.SZ)
- Target Healthcare REIT PLC (THRL.L)
- Mersen SA (MRN.PA)
- OPPENHEIMER HOLDINGS INC (OPY)
- Woori Technology Inc (032820.KQ)
- Jiangsu Zhengdan Chemical Industry Co Ltd (300641.SZ)
- Indus Holding (INH.DE)
Not investment advice. All data without warranty, price as of 06.11.2026. Details in the risk notice.